Compile Data Set for Download or QSAR
Report error Found 20 Enz. Inhib. hit(s) with all data for entry = 10174
LigandPNGBDBM651374(3-[(3S)-2-[1-[6-(4-Cyclopropyl-2-methyl-imidazol-1...)
Affinity DataIC50: 4.10nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651375(5-[(3S)-2-[1-[6-(4-Cyclopropyl-2-methyl-imidazol-1...)
Affinity DataIC50: 5.90nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651376(3-[(3S)-2-[1-[6-(2,5-Dimethylpyrazol-3-yl)pyrimidi...)
Affinity DataIC50: 7nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651377(3-Fluoro-5-[(3S)-2-[1-[6-(3-methyl-1,2,4-triazol-1...)
Affinity DataIC50: 8.10nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651370(3-Fluoro-5-[(3S)-2-[1-[6-(2-methylpyrazol-3-yl)pyr...)
Affinity DataIC50: 8.80nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651382([(3S)-3-(3,5-Difluorophenyl)isoxazolidin-2-yl]-[1-...)
Affinity DataIC50: 9nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651378(3-Fluoro-5-[(3S)-2-[1-[6-(5-methyl-1,2,4-triazol-1...)
Affinity DataIC50: 9.90nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651369(3-Fluoro-2-methyl-5-[(3S)-2-[1-[6-(2-methylimidazo...)
Affinity DataIC50: 12.1nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651379(3-Fluoro-5-[(3S)-2-[1-[6-(3-methyltriazol-4-yl)pyr...)
Affinity DataIC50: 13nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651372([(3S)-3-(3-Chloro-5-fluoro-phenyl)isoxazolidin-2-y...)
Affinity DataIC50: 13nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651380(3-Fluoro-5-[(3S)-2-[1-[5-fluoro-6-(2-methylimidazo...)
Affinity DataIC50: 14.9nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651368(3-Fluoro-5-[(3S)-2-[1-[6-(2-methylimidazol-1-yl)py...)
Affinity DataIC50: 15.8nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651364(Isoxazolidine of Comparator Example A | [(3S)-3-Ph...)
Affinity DataIC50: 16.4nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651373(3-Fluoro-5-[(3S)-2-[1-[6-(3-methyl-1H-pyrazol-4-yl...)
Affinity DataIC50: 17.8nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651381(3-Fluoro-5-[(3S)-2-[1-[5-fluoro-6-(4-methylpyrazol...)
Affinity DataIC50: 18.5nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651371([(3S)-3-(3,5-Difluorophenyl)isoxazolidin-2-yl]-[1-...)
Affinity DataIC50: 25nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651366(Isoxazolidin of Comparator Example C | [1-[6-(5-Me...)
Affinity DataIC50: 31nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651367(Substituted Phenyl-Isoxazolidin of Comparator Exam...)
Affinity DataIC50: 35nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651365(GSK WO2018 092089, Example 129 | [1-[6-(5-Methyl-1...)
Affinity DataIC50: 37nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent

LigandPNGBDBM651363(GSK WO2018 092089, Example 4 | (3-Phenyl-3,4-dihyd...)
Affinity DataIC50: 41nMAssay Description:In detail, 2 μl recombinantly produced hRIPK1 (aa 1-375) fusion protein (end concentration 3.6 μg/ml) and 2 μl compound (end concentra...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/18/2024
Entry Details
Go to US Patent